Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis – BMC Infectious … – BMC Infectious Diseases

Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html. Accessed 28 Dec 2022.

Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, Villamizar-Pena R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623.

PubMed PubMed Central Google Scholar

McIntosh JA, Benkovics T, Silverman SM, Huffman MA, Kong J, Maligres PE, et al. Engineered Ribosyl-1-kinase enables concise synthesis of molnupiravir, an antiviral for COVID-19. ACS Cent Sci. 2021;7(12):19805.

CAS PubMed PubMed Central Google Scholar

Abdulla ZA, Al-Bashir SM, Al-Salih NS, Aldamen AA, Abdulazeez MZ. A summary of the SARS-CoV-2 vaccines and technologies available or under development. Pathogens. 2021;10(7):788.

CAS PubMed PubMed Central Google Scholar

Francis MJ. Recent advances in vaccine technologies. Vet Clin North Am Small Anim Pract. 2018;48(2):23141.

PubMed Google Scholar

Khoshnood S, Ghanavati R, Shirani M, Ghahramanpour H, Sholeh M, Shariati A, et al. Viral vector and nucleic acid vaccines against COVID-19: a narrative review. Front Microbiol. 2022;13:984536.

PubMed PubMed Central Google Scholar

Pollet J, Chen WH, Strych U. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Adv Drug Deliv Rev. 2021;170:7182.

CAS PubMed PubMed Central Google Scholar

Cheng H, Peng Z, Luo W, Si S, Mo M, Zhou H, et al. Efficacy and safety of COVID-19 vaccines in phase III trials: a meta-analysis. Vaccines (Basel). 2021;9(6):582.

CAS PubMed Google Scholar

Sathian B, Asim M, Banerjee I, Roy B, Pizarro AB, Mancha MA, et al. Development and implementation of a potential coronavirus Disease 2019 (COVID-19) vaccine: a systematic review and meta-analysis of vaccine clinical trials. Nepal J Epidemiol. 2021;11(1):95982.

PubMed PubMed Central Google Scholar

Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines (Basel). 2021;9(5):467.

CAS PubMed Google Scholar

Calzetta L, Ritondo BL, Coppola A, Matera MG, Di Daniele N, Rogliani P. Factors influencing the efficacy of COVID-19 vaccines: a quantitative synthesis of phase III trials. Vaccines (Basel). 2021;9(4):341.

CAS PubMed Google Scholar

Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep. 2021;11(1):22777.

ADS CAS PubMed PubMed Central Google Scholar

Kumar S, Saikia D, Bankar M, Saurabh MK, Singh H, Varikasuvu SR, et al. Efficacy of COVID-19 vaccines: a systematic review and network meta-analysis of phase 3 randomized controlled trials. Pharmacol Rep. 2022;74:110.

Google Scholar

Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):77784.

PubMed Google Scholar

Higgins JPT, Savovi J, Page MJ, Elbers RG. JAC S. Chapter 8: Assessing risk of bias in a randomized trial. (updated February 2020). Cochrane, 2021. Preprint at http://www.training.cochrane.org/handbook (2021).

Good Clinical Practice. : GLOSSARY. https://ichgcp.net/1-glossary. Accessed 28 Dec 2022.

Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):16371.

PubMed Google Scholar

Shim SR, Kim SJ, Lee J, Rcker G. Network meta-analysis: application and practice using R software. Epidemiol Health. 2019;41:e2019013.

PubMed PubMed Central Google Scholar

Neupane B, Richer D, Bonner AJ, Kibret T, Beyene J. Network meta-analysis using R: a review of currently available automated packages. PLoS ONE. 2014;9(12):e115065.

ADS PubMed PubMed Central Google Scholar

Seide SE, Jensen K, Kieser M. A comparison of bayesian and frequentist methods in random-effects network meta-analysis of binary data. Res Synth Methods. 2020;11(3):36378.

PubMed Google Scholar

Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021;398(10317):217384.

CAS PubMed PubMed Central Google Scholar

Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 Infection in adults: a randomized clinical trial. JAMA. 2021;326(1):3545.

CAS PubMed Google Scholar

Tanriover MD, Doganay HL, Akova M, Guner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):21322.

CAS PubMed PubMed Central Google Scholar

Palacios R, Batista AP, Albuquerque CSN, Patio EG, Santos JdP, Conde MTRP, et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: The PROFISCOV study. SSRN J. 2021. https://doi.org/10.2139/ssrn.3822780.

Fadlyana E, Rusmil K, Tarigan R, Rahmadi AR, Prodjosoewojo S, Sofiatin Y, et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 1859 years: an interim analysis in Indonesia. Vaccine. 2021;39(44):65208.

CAS PubMed PubMed Central Google Scholar

Khairullin B, Zakarya K, Orynbayev M, Abduraimov Y, Kassenov M, Sarsenbayeva G, et al. Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in, in healthy adults: a multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up. EClinicalMedicine. 2022;50:101526.

PubMed PubMed Central Google Scholar

Mohraz M, Vahdat K, Ghamari SH, Abbasi-Kangevari M, Ghasemi E, Ghabdian Y, et al. Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial. BMJ. 2023;382:e070464.

PubMed PubMed Central Google Scholar

El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021;385(19):177485.

PubMed Google Scholar

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):260315.

CAS PubMed Google Scholar

Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ, Bonten M, Chandler R, et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2022;22(3):32940.

CAS PubMed Google Scholar

Khobragade A, Bhate S, Ramaiah V, Deshpande S, Giri K, Phophle H, et al. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet. 2022;399(10332):131321.

CAS PubMed PubMed Central Google Scholar

Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):67181.

CAS PubMed PubMed Central Google Scholar

Sadoff J, Gray G, Vandebosch A, Crdenas V, Shukarev G, Grinsztejn B, et al. Final analysis of efficacy and safety of single-dose Ad26.COV2.S. N Engl J Med. 2022;386(9):84760.

CAS PubMed Google Scholar

Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):88191.

CAS PubMed PubMed Central Google Scholar

Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med. 2021;385(25):234860.

CAS PubMed Google Scholar

Halperin SA, Ye L, MacKinnon-Cameron D, Smith B, Cahn PE, Ruiz-Palacios GM, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2022;399(10321):23748.

CAS PubMed Google Scholar

Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385(13):117283.

CAS PubMed Google Scholar

Dunkle LM, Kotloff KL, Gay CL, ez G, Adelglass JM, Barrat Hernndez AQ, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2022;386(6):53143.

CAS PubMed Google Scholar

Bravo L, Smolenov I, Han HH, Li P, Hosain R, Rockhold F, et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2022;399(10323):46172.

CAS PubMed PubMed Central Google Scholar

Dai L, Gao L, Tao L, Hadinegoro SR, Erkin M, Ying Z, et al. Efficacy and safety of the RBD-dimer-based Covid-19 vaccine ZF2001 in adults. N Engl J Med. 2022;386(22):2097111.

CAS PubMed Google Scholar

Tabarsi P, Anjidani N, Shahpari R, Mardani M, Sabzvari A, Yazdani B, et al. Evaluating the efficacy and safety of SpikoGen, an Advax-CpG55.2adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial. Clin Microbiol Infect. 2023;29(2):21520.

CAS PubMed Google Scholar

Hernndez-Bernal F, Ricardo-Cobas MC, Martn-Bauta Y, Rodrguez-Martnez E, Urrutia-Prez K, Urrutia-Prez K, et al. A phase 3, randomised, double-blind, placebo-controlled clinical trial evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine in adults (ABDALA-3 study). Lancet Reg Health Am. 2023;21:100497.

PubMed PubMed Central Google Scholar

Ryzhikov AB, Ryzhikov EA, Bogryantseva MP, Usova SV, Nechaeva EA, Danilenko ED et al. Assessment of safety and prophylactic efficacy of the EpiVacCorona peptide vaccine for COVID-19 prevention (phase III). Vaccines. 2023;11(5).

Mostafavi E, Eybpoosh S, Karamouzian M, Khalili M, Haji-Maghsoudi S, Salehi-Vaziri M, et al. Efficacy and safety of a protein-based SARS-CoV-2 vaccine: a randomized clinical trial. JAMA Netw Open. 2023;6(5):e2310302.

PubMed PubMed Central Google Scholar

Hager KJ, Prez Marc G, Gobeil P, Diaz RS, Heizer G, Llapur C, et al. Efficacy and safety of a recombinant plant-based adjuvanted Covid-19 vaccine. N Engl J Med. 2022;386(22):208496.

CAS PubMed Google Scholar

Korang SK, von Rohden E, Veroniki AA, Ong G, Ngalamika O, Siddiqui F, et al. Vaccines to prevent COVID-19: a living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials. PLoS ONE. 2022;17(1):e0260733.

CAS PubMed PubMed Central Google Scholar

Kouhpayeh H, Ansari H. Adverse events following COVID-19 vaccination: a systematic review and meta-analysis. Int Immunopharmacol. 2022;109:108906.

CAS PubMed PubMed Central Google Scholar

Park JW, Lagniton PNP, Liu Y, Xu RH. mRNA vaccines for COVID-19: what, why and how. Int J Biol Sci. 2021;17(6):144660.

CAS PubMed PubMed Central Google Scholar

Garcia-Beltran WF, Lam EC, St Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):237283e9.

CAS PubMed PubMed Central Google Scholar

Jara A, Undurraga EA, Gonzlez C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021;385(10):87584.

CAS PubMed Google Scholar

Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med. 2021;385(24):224151.

CAS PubMed Google Scholar

Anderson EJ, Creech CB, Berthaud V, Piramzadian A, Johnson KA, Zervos M, et al. Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age. N Engl J Med. 2022;387(18):167387.

CAS PubMed Google Scholar

Creech CB, Anderson E, Berthaud V, Yildirim I, Atz AM, Melendez Baez I, et al. Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age. N Engl J Med. 2022;386(21):201123.

See the original post here:

Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis - BMC Infectious ... - BMC Infectious Diseases

Related Posts
Tags: